Meeting
2015 ASCO Annual Meeting
Phase I expansion cohort trial to investigate the safety and clinical activity of avelumab (MSB0010718C) in patients with metastatic or locally advanced solid tumors.
Authors
Christopher Ryan Heery
Laboratory of Tumor Immunology and Biology, NCI, NIH, Bethesda, MD
Christopher Ryan Heery , Jeffrey R. Infante , Nicholas Iannotti , Karen Kelly , Petros Nikolinakos , Anja von Heydebreck , Kevin M. Chin , James L. Gulley
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCT01772004
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS3101)
DOI
10.1200/jco.2015.33.15_suppl.tps3101
Abstract #
TPS3101
Poster Bd #
420a
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study.
First Author: Karen Kelly
First Author: Igor Tsaur
Poster
2021 ASCO Annual Meeting
Phase I INSIGHT platform trial: Advanced safety and efficacy data from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced solid tumors.
First Author: Thorsten Oliver Goetze
Poster
2020 ASCO Virtual Scientific Program
Open-label, phase I study evaluating feasibility and safety of subcutaneous IMP321 (LAG-3Ig fusion protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities: Results from stratum D of the INSIGHT platform trial.
First Author: Thorsten Oliver Goetze